1,721,025 research outputs found
Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs
No full textIn our first lesson together we used to ask to our students "what is the price of a life?". The answer was always "there is no price of a life". Although nice, it’s not true; unfortunately, the only costless man is a dead one. In the last few years there has been a heated debate about cost and benefit in oncology, focused in particular on breast cancer screening and the availability and affordability of new drugs. In our opinion, an affordable, ethically and politically correctbudget for healthcare is government issued as part of a social healthcare system. In this context, all governments should declare how much is affordable in relationship with the economic situation of the country and decide what drugs and treatments can be provided for free (as part of a life-long system of national taxation) and which canno
Effectiveness of magnetotheraphy in resolution of some early complications of the mastectomy operation.
No full textLow frequency pulsated magnetic fields were administered to patients recently operated upon for mastectomy. The effect of the magnetic fields was that of accelerating the repair of the surgical wound, of reducing the local oedema, of minimizing local pain and of enhancing the functional recovery of the shoulder when affected by post-operative periarthritis
Cancro del fegato: possibilità di diagnosi precoce
No full textDa molti anni l'Istituo di Anatomia Pastologica di Trieste conduce un intenso lavoro di verifica delle diagnosi cliniche tramite lo strumento del risconro autoptico eseguito in manier sistematica su tutti i soggetti...
The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study.
No full textThe role of taxanes in triple-negative breast cancer: literature review
No full textBreast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs. In this review, data on the use of taxanes in triple-negative BCs are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and metastatic). Further, the role of nab-paclitaxel (formulation of albumin-bound paclitaxel) in these tumors is also evaluated. The available data show the clinical potential of nab-paclitaxel based combinations in terms of long-duration response, increased survival, and better quality of life of patients with triple-negative metastatic BC. The ongoing trials will give further information on the better management of this type of tumor
Annual Hazard Rates of Recurrence for early breast cancer. What has changed in the last 10 years? Results from the NORA study.
No full text
- …
